Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ADA | P00813 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108176 | 0.90 | METTL3 (0.55) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL12108173 | 0.88 | METTL3 (0.60) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL1301704 | 0.86 | METTL3 (0.70) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL12108160 | 0.86 | METTL3 (0.55) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL12108158 | 0.86 | METTL3 (0.56) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL1045214 | 0.85 | METTL3 (0.55) | METTL3GAAHTTMETTL14MAPT | |
| SCHEMBL1045212 | 0.85 | METTL3 (0.55) | METTL3GAAHTTMETTL14MAPT | |
| SCHEMBL12108172 | 0.85 | METTL3 (0.53) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL12108164 | 0.84 | METTL3 (0.60) | METTL3GAAHTTCFDMRGPRX4 | |
| SCHEMBL12108188 | 0.84 | METTL3 (0.46) | METTL3GAAHTTCFDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885GAA 176/4885HTT 4411/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885GAA 176/4885HTT 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.